Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Dyax Strikes Deal for Chinese Sales of Drug
Feb. 8, 2013
Dyax of Burlington said it is partnering with CVie Therapeutics to develop and commercialize its drug Kalbitor in China, Hong Kong and Macau. Kalbitor is used to treat hereditary angioedema, a rare, genetic condition affecting the immune system that causes swelling of the face and airways, abdominal cramping and other angioedema indications.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing